

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A

AQS




FIG. 6B

Control, unreduced antibody




FIG. 7




FIG. 8A

Lipoic acid




FIG. 8B

Control, unreduced antibody




FIG. 9




FIG. 10




FIG. 11




FIG. 12 A




FIG. 12 B

Sample	Time	% Fragments	% Intact IgG
Untreated	0 h	7.4	92.6
No AQC	2 h	31.1	68.9
+ AQC	2 h	None	100
No AQC	6 h	77.2	22.8
+ AQC	6 h	6.3	93.7
No AQC	24 h	89.6	5.7
+ AQC	24 h	5.0	90.3
No AQC	48 h	98.2	1.8
+ AQC	48 h	5.2	94.8
No AQC	68 h	97.8	2.2
+ AQC	68 h	10.4	89.6

FIG. 13A

Cystine dimethyl ester (CDME)




FIG. 13B

Control, unreduced antibody




FIG. 14




FIG. 15





FIG. 16

FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22

